Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Ross C. Donehower"'
Autor:
Cara Wilt, Jin He, Amy Ryan, Lei Zheng, Christi Walsh, Georgios Gemenetzis, Anne Marie Lennon, Dung T. Le, Vikesh K. Singh, Valerie Lee, Mouen A. Khashab, Eun Ji Shin, Lindsay Parish, Ding Ding, Chunhui Yuan, Daniel A. Laheru, Lindsey Manos, Elizabeth D. Thompson, Lara Groshek, Keith McIntyre, Dea Cunningham, Ross C. Donehower, Ana De Jesus-Acosta, Rachel Klein, John L. Cameron, Nilo Azad, Mary Hodgin, Alex B. Blair, Robert A. Anders, Elliot K. Fishman, Carol Judkins, Ammar A. Javed, William R. Burns, Jonathan Teinor, Amol Narang, Zunaira N. Javed, Richard A. Burkhart, Alison P. Klein, Adrian Murphy, Nicholas J. Roberts, Michael J. Wright, Christopher L. Wolfgang, Matthew J. Weiss, Elizabeth M. Jaffee, Amy Hacker-Prietz, Jun Yu, Atif Zaheer, Caitlin Brown, Ralph H. Hruban, Vincent P. Groot
Publikováno v:
Cancer letters
Recent research on genomic profiling of pancreatic ductal adenocarcinoma (PDAC) has identified many potentially actionable alterations. However, the feasibility of using genomic profiling to guide routine clinical decision making for PDAC patients re
Autor:
Chang Xia, Elliot K. Fishman, Amanda L. Blackford, Kelly Olino, Christopher L. Wolfgang, Lei Zheng, David Cosgrove, Hua Ling Tsai, Ralph H. Hruban, Daniel A. Laheru, Luis A. Diaz, Ross C. Donehower, Farzana A. Faisal, Barish H. Edil, Joseph M. Herman, Nilofer S. Azad, Richard D. Schulick, Dung T. Le, Zeshaan A. Rasheed, Ana De Jesus-Acosta
Publikováno v:
American Journal of Clinical Oncology. 39:18-26
Objectives At diagnosis, 30% of patients with pancreatic cancer are unresectable stage 3 locally advanced. The standard treatment for locally advanced pancreatic cancer (LAPC) is not defined. The current study was conducted to assess the roles of che
Autor:
Nickolas Papadopoulos, Nianqing Xiao, Robert A. Anders, Kristen K. Ciombor, Shibin Zhou, Katherine M. Bever, Cara Wilt, Bao H. Lam, Hao Wang, Janis M. Taube, George A. Fisher, Matthias Holdhoff, Fay Wong, Richard M. Goldberg, Amanda N. Fader, Ludmila Danilova, Jennifer N. Durham, Laveet K. Aulakh, David Spetzler, Leslie Cope, Dung T. Le, Christian F. Meyer, Franck Housseau, James J. Lee, Aleksandra Eyring, Andrew K. Joe, James R. Eshleman, Deborah K. Armstrong, Bjarne Bartlett, Kellie N. Smith, Brandon Luber, Agnieszka A. Rucki, Daniel A. Laheru, Steve Lu, Nilofer S. Azad, Todd S. Crocenzi, Kenneth W. Kinzler, Tim F. Greten, Austin G. Duffy, Bert Vogelstein, Drew M. Pardoll, Luis A. Diaz, Atif Zaheer, Holly Kemberling, S. Peter Kang, Ross C. Donehower
Predicting responses to immunotherapy Colon cancers with loss-of-function mutations in the mismatch repair (MMR) pathway have favorable responses to PD-1 blockade immunotherapy. In a phase 2 clinical trial, Le et al. showed that treatment success is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee4527179e77e9a993495411588f44d3
https://europepmc.org/articles/PMC5576142/
https://europepmc.org/articles/PMC5576142/
Autor:
Elizabeth A. Sugar, Daniel A. Laheru, Sara Solt, Dung T. Le, Jennifer N. Uram, Ross C. Donehower, Beth Onners, Luis A. Diaz, Lei Zheng, Elizabeth M. Jaffee, Eric R. Lutz
Publikováno v:
Journal of Immunotherapy. 36:382-389
Preclinical reports support the concept of synergy between cancer vaccines and immune checkpoint blockade in nonimmunogenic tumors. In particular, cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibodies have been successfully combined with GM
Autor:
Ramesh K. Ramanathan, Scott McKane, Scott M. Hynes, Stephen P. Anthony, Karen Lewandowski, Tara Iyengar, Eric H. Westin, Glen J. Weiss, Karla Hurt, Ross C. Donehower
Publikováno v:
Investigational New Drugs. 31:136-144
Purpose This phase I study aims at assessing the safety and tolerability of LY2603618, a selective inhibitor of Checkpoint Kinase 1, in combination with pemetrexed and determining the maximum tolerable dose and the pharmacokinetic parameters. Experim
Autor:
Wells A. Messersmith, Piotr Kulesza, Christine A. Iacobuzio-Donahue, Daniel A. Laheru, Michelle A. Rudek, Janet Dancey, Antonio Jimeno, Manuel Hidalgo, Ming Zhao, Michael A. Carducci, Yasmin Kahn, Heather A. Jacene, Alexander I. Spira, Ross C. Donehower
Publikováno v:
Clinical Colorectal Cancer. 9:297-304
This phase I study was conducted to determine the maximum tolerated dose (MTD) of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) in patients with advanced colorectal
Autor:
Sharyn D. Baker, James A. Zwiebel, Richard F. Ambinder, Anchalee Jiemjit, Ross C. Donehower, Ming Zhao, Michael A. Carducci, Michelle A. Rudek, Jianqing Lin, S D Gore, Jill Gilbert, James G. Herman
Publikováno v:
Clinical Cancer Research. 15:6241-6249
Purpose: This was a phase I trial to determine the minimal effective dose and optimal dose schedule for 5-azacytidine (5-AC) in combination with sodium phenylbutyrate in patients with refractory solid tumors. The pharmacokinetics, pharmacodynamics, a
Autor:
Kurtis A. Campbell, Michael J. Swartz, Jordan M. Winter, Charles C. Hsu, John L. Cameron, Charles J. Yeo, F. Asrari, Joseph M. Herman, Elizabeth M. Jaffee, Luis A. Diaz, Christopher L. Wolfgang, Elizabeth A. Sugar, Ross C. Donehower, Ross A. Abrams, Manuel Hidalgo, Richard D. Schulick, Ralph H. Hruban, Ray Robinson, Daniel A. Laheru, Timothy M. Pawlik
Publikováno v:
Journal of Clinical Oncology. 26:3503-3510
PurposeTo examine the efficacy of adjuvant chemoradiotherapy after pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma (PC) in patients undergoing resection at Johns Hopkins Hospital (JHH; Baltimore, MD).Patients and MethodsBetween August 30,
Autor:
Daniel A. Laheru, Wells A. Messersmith, Manuel Hidalgo, Wen Wee Ma, Antonio Jimeno, Carlton K. K. Lee, Ross C. Donehower, Sharyn D. Baker
Publikováno v:
Annals of Oncology. 19:374-379
Background Troxacitabine is a novel L-nucleoside analogue. Preclinical studies showed improved activity with infusions of at least 3 days compared with bolus regimens, especially at concentrations >20 ng/ml. This phase I study tested the feasibility
Autor:
Connie Collins, Ming Zhao, Sharyn D. Baker, Ross C. Donehower, Michael A. Carducci, Wells A. Messersmith, Michelle A. Rudek, A. Dimitrios Colevas, Antonio C. Wolff
Publikováno v:
European Journal of Cancer. 43:78-86
A phase I study of Dimethylamino Benzoylphenylurea (BPU), a tubulin inhibitor, was performed using a weekly continuous schedule. Patients with refractory solid tumours received oral BPU once weekly without interruption at doses ranging from 5 to 320m